Xvivo Perfusion AB (XVIVO)

Currency in SEK
188.80
-2.10(-1.10%)
Closed·
XVIVO Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
XVIVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
188.80193.30
52 wk Range
188.70541.00
Key Statistics
Prev. Close
190.9
Open
193.3
Day's Range
188.8-193.3
52 wk Range
188.7-541
Volume
80.83K
Average Volume (3m)
135.48K
1-Year Change
-63.22%
Book Value / Share
66.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XVIVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
355.00
Upside
+88.03%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Xvivo Perfusion AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Xvivo Perfusion AB Company Profile

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Employees
193
Market
Sweden

Xvivo Perfusion AB Earnings Call Summary for Q2/2025

  • XVivo reports 11% decline in organic growth for Q2 2025, with net sales of SEK 178 million; stock plunges 27.74% in pre-market trading
  • Gross margin remains stable at 74%; adjusted EBITDA at 13%; negative currency effect of 6% on sales impacts overall performance
  • Company prepares to launch heart product in Europe and Pacific; aims to start liver clinical trial in US by Q3 2025
  • CEO acknowledges disappointing quarter but emphasizes long-term potential and commitment to strategic goals
  • XVivo maintains strong financial fundamentals with current ratio of 5.2 and revenue growth of 33% over last twelve months
Last Updated: 11/07/2025, 14:16
Read Full Transcript

Compare XVIVO to Peers and Sector

Metrics to compare
XVIVO
Peers
Sector
Relationship
P/E Ratio
54.3x25.1x−0.5x
PEG Ratio
−4.840.010.00
Price/Book
2.9x2.2x2.6x
Price / LTM Sales
7.3x2.1x3.3x
Upside (Analyst Target)
98.6%0.0%43.5%
Fair Value Upside
Unlock20.1%6.8%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 355.00
(+88.03% Upside)

Earnings

Latest Release
Jul 11, 2025
EPS / Forecast
0.05 / 0.6172
Revenue / Forecast
178.00M / 218.12M
EPS Revisions
Last 90 days

XVIVO Income Statement

People Also Watch

323.1
NOVOb
+4.60%
18.450
IVG
+0.11%
616.90
ASML
+1.02%
125.60
CAPP
+1.45%
22.90
HTRO
+3.48%

FAQ

What Stock Exchange Does Xvivo Perfusion AB Trade On?

Xvivo Perfusion AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Xvivo Perfusion AB?

The stock symbol for Xvivo Perfusion AB is "XVIVO."

What Is the Xvivo Perfusion AB Market Cap?

As of today, Xvivo Perfusion AB market cap is 5.95B.

What Is Xvivo Perfusion AB's Earnings Per Share (TTM)?

The Xvivo Perfusion AB EPS (TTM) is 3.54.

When Is the Next Xvivo Perfusion AB Earnings Date?

Xvivo Perfusion AB will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is XVIVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Xvivo Perfusion AB Stock Split?

Xvivo Perfusion AB has split 0 times.

How Many Employees Does Xvivo Perfusion AB Have?

Xvivo Perfusion AB has 193 employees.

What is the current trading status of Xvivo Perfusion AB (XVIVO)?

As of 09 Aug 2025, Xvivo Perfusion AB (XVIVO) is trading at a price of 188.80, with a previous close of 190.90. The stock has fluctuated within a day range of 188.80 to 193.30, while its 52-week range spans from 188.70 to 541.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.